BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pancreatic Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Pancreatic Cancer\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05093231-2028@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Olaparib: Phase 2 readout est. (NCT05093231)
DESCRIPTION:Olaparib\, phase 2\, Pancreatic Cancer.\nStudy: Pembrolizumab W
 ith Olaparib as Combined Therapy in Metastatic Pancreatic Cancer\nEstimate
 d primary completion: 30 November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/olaparib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05093231
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05736731-2310@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:A2B530: Phase 1/2 readout est. (NCT05736731)
DESCRIPTION:A2B530\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of A2B530\, a Logic-gated CAR T\, in
  Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Ex
 pression\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/a2b530#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05736731
URL:https://assetmemo.bio/drug/a2b530#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04115163-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT04115163)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclita
 xel for the Treatment of Metastatic Pancreatic Cancer\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04115163
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06759090-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06759090)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Metronomic 
 Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Adva
 nced Pancreatic Cancer\nEstimated primary completion: 15 January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06759090
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06770452-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:HRS-4642: Phase 2 readout est. (NCT06770452)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: HRS-4642 With N
 imotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreati
 c Cancer Patients\nEstimated primary completion: 1 February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/hrs-4642#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06770452
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05929885-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05929885)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Metronomic 
 Capecitabine\, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Meta
 static Pancreatic Cancer Patients\nEstimated primary completion: 28 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 29885
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547736-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HRS-4642: Phase 2 readout est. (NCT06547736)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: Exploratory Pla
 tform Research on Precision Therapy of Advanced Pancreatic Cancer\nEstimat
 ed primary completion: March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/hrs-4642#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06547736
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03523312-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Capecitabine: Phase 2 readout est. (NCT03523312)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Use of High
 -dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Sur
 gical Treatment in Patients With Locally Advanced Pancreatic Cancer\nEstim
 ated primary completion: April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03523312
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888674-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06888674)
DESCRIPTION:Capecitabine\, phase 1/2\, Pancreatic Cancer.\nStudy: Personali
 zed Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pan
 creatic Cancer.\nEstimated primary completion: 1 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06888674
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06938282-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:HRS-4642: Phase 2 readout est. (NCT06938282)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: An Exploratory 
 Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemother
 apy for Pancreatic Cancer\nEstimated primary completion: 30 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/hrs-4642#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06938282
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451043-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05451043)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Cancer.\nStudy: Durvalumab a
 nd Tremelimumab in Combination With Propranolol and Chemotherapy for Treat
 ment of Advanced Hepatopancreabiliary Tumors (BLOCKED)\nEstimated primary 
 completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/gemcitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05451043
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-2827@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Zoldonrasib: Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Zoldonrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate the Safety\, Tolerability & Efficacy of TNG462 in Combina
 tion in PDAC & NSCLC Patients\nEstimated primary completion: June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/zoldonrasib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06922591
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427239-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HRS-4642: Phase 1/2 readout est. (NCT06427239)
DESCRIPTION:HRS-4642\, phase 1/2\, Pancreatic Cancer.\nStudy: Exploratory C
 linical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Ad
 vanced Pancreatic Ductal Adenocarcinoma\nEstimated primary completion: Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-4642#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06427239
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06587061-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HRS-4642: Phase 2 readout est. (NCT06587061)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: HRS-4642 in Com
 bination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Canc
 er\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/hrs-4642#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06587061
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131514-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HRS-4642: Phase 2 readout est. (NCT07131514)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: HRS-4642 in Com
 bination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for
  Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer\nEstimated primar
 y completion: June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/hrs-4642#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07131514
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692750-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07692750)
DESCRIPTION:Capecitabine\, phase 1/2\, Pancreatic Cancer.\nStudy: IBI343 Co
 mbined With Chemotherapy in Advanced Pancreatic Cancer\nEstimated primary 
 completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07692750
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483555-1960@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Erlotinib: Phase 1/2 readout est. (NCT06483555)
DESCRIPTION:Erlotinib\, phase 1/2\, Pancreatic Cancer.\nStudy: Basal-like P
 DAC Treated With Gemcitabine\, Erlotinib\, and Nab-paclitaxel\nEstimated p
 rimary completion: August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/erlotinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06483555
URL:https://assetmemo.bio/drug/erlotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423326-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT06423326)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Gemcitabine\, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for
  Patients With Resectable or Borderline Resectable Pancreatic Cancer\nEsti
 mated primary completion: 31 August 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06423326
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955940-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Capecitabine: Phase 2 readout est. (NCT02955940)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: An Open-Label Study to Enable Continued Treatment Access for Subject
 s Previously Enrolled in Studies of Ruxolitinib\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02955940
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296341-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HRS-4642: Phase 1/2 readout est. (NCT07296341)
DESCRIPTION:HRS-4642\, phase 1/2\, Pancreatic Cancer.\nStudy: HRS-4642 Comb
 ination With Other Antitumor Therapies in Patients With Solid Tumors\nEsti
 mated primary completion: October 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/hrs-4642#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07296341
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691593-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HRS-4642: Phase 2 readout est. (NCT07691593)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: Neoadjuvant HRS
 -4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cance
 r\nEstimated primary completion: October 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/hrs-4642#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07691593
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03492671-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT03492671)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Cancer.\nStudy: Testing the 
 Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surg
 ery in Localized Pancreatic Cancer\nEstimated primary completion: October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0349267
 1
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438106-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HRS-4642: Phase 2 readout est. (NCT07438106)
DESCRIPTION:HRS-4642\, phase 2\, Pancreatic Cancer.\nStudy: A Phase II Stud
 y of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Convers
 ion Therapy for Locally Advanced Pancreatic Cancer\nEstimated primary comp
 letion: October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /hrs-4642#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07438106
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828756-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07828756)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Albumin-bou
 nd Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer\nEstimated pri
 mary completion: 31 October 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07828756
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04858334-2028@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Olaparib: Phase 2 readout est. (NCT04858334)
DESCRIPTION:Olaparib\, phase 2\, Pancreatic Cancer.\nStudy: APOLLO: A Rando
 mized Phase II Double-Blind Study of Olaparib Versus Placebo Following Cur
 ative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pat
 hogenic BRCA1\, BRCA2 or PALB2 Mutation\nEstimated primary completion: 31 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olapari
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 858334
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026905-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05026905)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Cancer.\nStudy: A Phase II R
 andomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1
 /LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pan
 creatic Cancer\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05026905
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06115499-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT06115499)
DESCRIPTION:Gemcitabine\, phase 2/3\, Pancreatic Ductal Adenocarcinoma.\nSt
 udy: The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treat
 ment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cance
 r\nEstimated primary completion: 1 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06115499
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683315-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT04683315)
DESCRIPTION:Gemcitabine\, phase 2\, Pancreatic Cancer.\nStudy: PurIST Class
 ification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profi
 ling of EUS Aspiration Samples\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0468331
 5
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03682289-2028@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Olaparib: Phase 2 readout est. (NCT03682289)
DESCRIPTION:Olaparib\, phase 2\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: Ceralasertib (AZD6738) Alone and in Combination With Olapar
 ib or Durvalumab in Patients With Solid Tumors\nEstimated primary completi
 on: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ol
 aparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03682289
URL:https://assetmemo.bio/drug/olaparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04543071-3051@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Motixafortide: Phase 2 readout est. (NCT04543071)
DESCRIPTION:Motixafortide\, phase 2\, Pancreatic Cancer.\nStudy: Chemo4METP
 ANC Combination Chemokine Inhibitor\, Immunotherapy\, and Chemotherapy in 
 Pancreatic Adenocarcinoma\nEstimated primary completion: June 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/motixafortide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04543071
URL:https://assetmemo.bio/drug/motixafortide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562152-2540@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Atebimetinib: Phase 3 readout est. (NCT07562152)
DESCRIPTION:Atebimetinib\, phase 3\, Pancreatic Cancer.\nStudy: Atebimetini
 b + GnP as a First Line Treatment in Patients With Metastatic Pancreatic A
 denocarcinoma\nEstimated primary completion: June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/atebimetinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07562152
URL:https://assetmemo.bio/drug/atebimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07945782-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Gemcitabine: Phase 1/2 readout est. (NCT07945782)
DESCRIPTION:Gemcitabine\, phase 1/2\, Pancreatic Cancer.\nStudy: A Phase I/
 II Single-Arm\, Open-Label\, Exploratory Study Evaluating the Safety and E
 fficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine
  and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer\nE
 stimated primary completion: 30 June 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07945782
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07833241-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07833241)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Surufatinib
  in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemoth
 erapy for Neoadjuvant Therapy of HRPC or BRPC\nEstimated primary completio
 n: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07833241
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03351296-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT03351296)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Two Chemoth
 erapy Regimens Plus or Minus Bevacizumab\nEstimated primary completion: De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecita
 bine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03351296
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621718-2827@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Zoldonrasib: Phase 3 readout est. (NCT07621718)
DESCRIPTION:Zoldonrasib\, phase 3\, Pancreatic Cancer.\nStudy: Study of Zol
 donrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigat
 or's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancre
 atic Adenocarcinoma ( RASolute 305 )\nEstimated primary completion: 30 Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zoldonras
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7621718
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806058-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-4642: Phase 1/2 readout est. (NCT07806058)
DESCRIPTION:HRS-4642\, phase 1/2\, Pancreatic Cancer.\nStudy: An Open-Label
 \, Multicenter\, Phase IB/II Clinical Study of HRS-7172 in Combination Wit
 h Antitumor Therapy in Participants With Solid Tumors\nEstimated primary c
 ompletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/hrs-4642#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07806058
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897644-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT06897644)
DESCRIPTION:Gemcitabine\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nStud
 y: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuati
 on of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanc
 ed Pancreatic Cancer.\nEstimated primary completion: 1 January 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06897644
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805954-2827@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zoldonrasib: Phase 3 readout est. (NCT07805954)
DESCRIPTION:Zoldonrasib\, phase 3\, Pancreatic Cancer.\nStudy: Study of Zol
 donrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Na
 b-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancr
 eatic Adenocarcinoma\nEstimated primary completion: March 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zoldonrasib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07805954
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232875-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:HRS-4642: Phase 3 readout est. (NCT07232875)
DESCRIPTION:HRS-4642\, phase 3\, Pancreatic Cancer.\nStudy: HRS 4642 Inject
 ion Combined With AG Versus Placebo Combined With AG Therapy in First-Line
  Advanced or Metastatic Pancreatic Cancer\nEstimated primary completion: A
 pril 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-4642#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07232
 875
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155629-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT07155629)
DESCRIPTION:Gemcitabine\, phase 3\, Pancreatic Cancer.\nStudy: Neoadjuvant 
 Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer\nEstimated p
 rimary completion: 31 August 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07155629
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958328-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20301021
DTEND;VALUE=DATE:20301022
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06958328)
DESCRIPTION:Capecitabine\, phase 3\, Pancreatic Cancer.\nStudy: Testing Hig
 her Dose Radiation Therapy for Locally Advanced Pancreatic Cancer\nEstimat
 ed primary completion: 21 October 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06958328
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900789-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Gemcitabine: Phase 3 readout est. (NCT07900789)
DESCRIPTION:Gemcitabine\, phase 3\, Pancreatic Cancer.\nStudy: HRS-4642 Com
 bined With Antitumor Agents for the Treatment of Perioperative Pancreatic 
 Cancer\nEstimated primary completion: 30 November 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07900789
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900789-11069@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:HRS-4642: Phase 3 readout est. (NCT07900789)
DESCRIPTION:HRS-4642\, phase 3\, Pancreatic Cancer.\nStudy: HRS-4642 Combin
 ed With Antitumor Agents for the Treatment of Perioperative Pancreatic Can
 cer\nEstimated primary completion: 30 November 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/hrs-4642#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07900789
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783140-7671@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20310602
DTEND;VALUE=DATE:20310603
SUMMARY:Gemcitabine: Phase 2/3 readout est. (NCT06783140)
DESCRIPTION:Gemcitabine\, phase 2/3\, Pancreatic Cancer.\nStudy: Study of N
 ABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Can
 cer\nEstimated primary completion: 2 June 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06783140
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02598349-9047@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20391031
DTEND;VALUE=DATE:20391101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT02598349)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Proton Radi
 ation for Unresectable\, Borderline Resectable\, or Medically Inoperable C
 arcinoma of the Pancreas\nEstimated primary completion: October 2039. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT02598349
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
